Francisco Pardo, MD
Addiction Medicine · San Diego, CANPI 1699844621
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 260 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 29 manufacturers, the largest accounting for just 18.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2021 at $1,161 and has fallen 62.3% since, to $438 in 2025. Among addiction medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 260 payments — averaging $23.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Gilead$970
- GSK$934
- EMD Serono, Inc.$594
- Lilly USA, LLC$317
- AbbVie$289
- plus $2K from 23 others
What the payments were for
- Travel & lodging$80%
- Food & beverage$5,981100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 56 | $1,099 |
| Gilead | 33 | $970 |
| GSK | 25 | $934 |
| EMD Serono, Inc. | 43 | $594 |
| Lilly USA, LLC | 16 | $317 |
| AbbVie | 15 | $289 |
| Merck | 13 | $238 |
| Janssen Products, LP | 2 | $237 |
| Kowa Pharmaceuticals America, Inc. | 12 | $198 |
| Neurocrine Biosciences, Inc. | 1 | $172 |
| Avanir Pharmaceuticals, Inc. | 1 | $126 |
| Amarin Pharma, Inc. | 6 | $120 |
| Eisai Inc. | 6 | $93 |
| Antares Pharma, Inc. | 4 | $90 |
| Johnson & Johnson | 4 | $74 |
| Pfizer | 3 | $62 |
| Theratechnologies Inc. | 3 | $61 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $56 |
| Novo Nordisk | 2 | $44 |
| Arbor Pharmaceuticals, Inc. | 2 | $37 |
| Dynavax Technologies Corporation | 1 | $31 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $23 |
| Novartis | 1 | $22 |
| Seqirus USA Inc | 1 | $21 |
| Aytu Biopharma, Inc. | 1 | $20 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| Halozyme Inc | 1 | $16 |
| Ultragenyx Pharmaceutical Inc. | 1 | $14 |
| Azurity Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,988 in reported general payments places this provider in the 90th percentile of 190 addiction medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 28 | $28,380 |
| BelsomraSuvorexant | 19 | $7,904 |
| XareltoRivaroxaban | 19 | $5,665 |
| OxycontinOxycodone Hcl | 11 | $5,472 |
| Oxycodone Hcl | 194 | $4,973 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 79 | $3,478 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 106 | $3,461 |
| Morphine Sulfate ErMorphine Sulfate | 64 | $1,479 |
| Gabapentin | 94 | $1,125 |
| Methadone Hcl | 12 | $625 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 11 | $553 |
| Diltiazem Hcl | 13 | $366 |
| Duloxetine Hcl | 24 | $294 |
| Atorvastatin Calcium | 34 | $285 |
| Tamsulosin Hcl | 18 | $254 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity | $317 | $28,38028 claims |
| MerckBelsomra | $238 | $7,90419 claims |
| Johnson & JohnsonXarelto | $74 | $5,66519 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 190 addiction medicine providers in California.
Other addiction medicine in San Diego
- Carolyn RossSan Diego$3K
- Puri Barin-TanjuaquioSan Diego$2K
- Tipu KhanVentura$262K
- Anthony AlbaneseMather$135K
- Matthew TorringtonCulver City$77K
- Kenneth StarrArroyo Grande$64K
- Drew PinskySouth Pasadena$60K
- Mark HonzelBeverly Hills$27K
- Bryan HylerVista$17K
- Abraham MalkinLos Angeles$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.